Bayer Ups Guidance While Pharma Head Highlights NHL Drug Copanlisib

 
• By Lucie Ellis-Taitt

Bayer has initiated the regulatory filing process in the US for its pipeline non-Hodgkin's lymphoma drug copanlisib, head of pharma Dieter Weinand said during the company's first quarter earnings call during which the German group also said it was upping guidance for the year.

Cancer cell
Bayer's pharma head zooms in on regulatory progress for NHL drug in 1Q earnings call

More from Strategy

More from Business